Skip to main content

Table 1 Predicted costs and effectiveness outcomes

From: Implementation of methadone therapy for opioid use disorder in Russia – a modeled cost-effectiveness analysis

 

MT supplied to 3.1% of OUD population

MT supplied to 12.5% of OUD population

MT supplied to 25% of OUD population

MT supplied to 55% of OUD population

 

Year

DALYsaAverted

Costa,b

DALYsaAverted

Costa,b

DALYsaAverted

Costa,b

DALYsaAverted

Costa,b

Cost/DALY Averteda,b

1

6,562

2,145,882

26,458

8,652,750

52,916

17,305,500

116,415

38,072,100

327

2

6,148

2,034,130

24,810

8,208,772

49,674

16,435,185

109,568

36,250,553

331

3

5,759

1,928,198

23,262

7,787,574

46,626

15,608,638

103,115

34,516,158

335

4

5,395

1,827,783

21,808

7,387,988

43,759

14,823,660

97,034

32,864,744

339

5

5,053

1,732,597

20,441

7,008,905

41,064

14,078,160

91,304

31,292,342

343

6

4,731

1,642,368

19,158

6,649,274

38,531

13,370,151

85,905

29,795,170

347

7

4,430

1,556,838

17,953

6,308,095

36,149

12,697,749

80,819

28,369,630

351

8

4,147

1,475,762

16,822

5,984,422

33,910

12,059,164

76,027

27,012,295

356

9

3,882

1,398,908

15,759

5,677,358

31,806

11,452,693

71,512

25,719,901

360

10

3,633

1,326,057

14,762

5,386,049

29,829

10,876,723

67,260

24,489,341

365

Present value

49,739

17,068,524

201,234

69,051,186

404,265

138,707,623

898,958

308,382,234

343

  1. aDiscounted at 3% after year 1; b2015 US Dollars